All Drug Discovery articles – Page 9
-
NewsOntario invests $3.1M in next-generation cancer therapeutics
The Ontario Institute for Cancer Research has awarded $3.1 million to four provincial research teams developing novel cancer therapies designed to overcome drug resistance and reduce treatment-related toxicity.
-
NewsChampions Oncology to present eight studies at AACR 2026
Champions Oncology will present eight studies at AACR 2026 spanning KRAS-mutant tumours, ovarian cancer, glioblastoma and emerging therapies including radiopharmaceuticals and CAR-T, using patient-derived models to improve early-stage decision-making in oncology drug development.
-
NewsInsilico announces ISM6200 AI-designed drug candidate for ovarian cancer and cortisol disorders
Insilico Medicine has nominated ISM6200, a preclinical drug candidate designed using generative AI to target NR3C1, a receptor involved in cortisol regulation.
-
NewsMassey Cancer Center funds drug discovery projects targeting Hsp27-CerS1 and ferroptosis pathways
The VCU Massey Comprehensive Cancer Center has awarded $50,000 each to two innovative drug discovery projects through its collaborative programme with Sanford Burnham Prebys Medical Discovery Institute.
-
ArticleAnalytica 2026: Connecting data across drug discovery workflows
Drug discovery is generating more data than ever, but the challenge is making sure that data is reliable, connected and usable. At Analytica 2026 in Munich, Drug Target Review spoke with technology developers and industry leaders across the exhibition floor to understand how these challenges are being addressed.
-
NewsZebrafish drug screening identifies precision therapies for autism
Yale University researchers have created a behavioural drug screening database using zebrafish models to identify FDA-approved compounds that reverse disrupted behaviours linked to autism risk genes.
-
NewsNew osteoarthritis therapy targeting joint repair advances following preclinical success
A Duke Health-led consortium has achieved key preclinical milestones in developing regenerative therapies that target cartilage and bone damage in osteoarthritis, potentially offering an alternative to symptom management and joint replacement surgery.
-
ArticleAI builds dual-action cancer drug targeting PKMYT1
Research published in Nature Communications shows how generative AI can be used to design complex dual-action cancer drug candidates. Insilico Medicine has developed a PKMYT1 degrader that both eliminates the target protein and blocks its activity, demonstrating the growing role of AI in advanced drug discovery.
-
News3D-printed drug carriers deliver chemotherapy directly to tumours
Novel FRESH 3D printing technology enables fabrication of nanoscale spanlastic carriers for localised anticancer drug delivery. Early in vitro studies have demonstrated enhanced cellular uptake and tumour cell killing whilst potentially minimising systemic toxicity associated with conventional chemotherapy administration.
-
ArticleImproving selectivity in antibody–drug conjugates
Promatix Biosciences is developing a new generation of bispecific antibody–drug conjugates using proprietary membrane proteomics data to identify highly selective target pairings. CEO Dr Michael Hunter explains how the company’s TXPro database enables discovery of previously unexplored tumour biology to improve therapeutic index and reduce on-target/off-tumour toxicities in solid tumours.
-
ArticleOperational data: the hidden driver of faster drug discovery
The key to faster, smarter drug discovery lies in data that’s often overlooked. By exposing hidden delays and inefficiencies, this data enables teams to shorten discovery cycles and progress promising candidates faster.
-
NewsSmall molecule SK-129 targets protein aggregation in Parkinson’s disease
International researchers have identified a small molecule capable of crossing the blood-brain barrier to prevent pathological protein aggregation in Parkinson’s disease, Lewy body dementia and multiple system atrophy.
-
ArticleFrom fragments to maps: scaling drug–target interaction data
Most drug–target data were never designed to be compared at scale. Pharmome mapping takes a different approach, building a shared dataset intended to support more predictable discovery.
-
NewsDNA-based system delivers targeted cancer drugs via biomarker logic
Researchers at the University of Geneva have developed a DNA-based drug delivery platform that uses molecular logic gates to identify cancer cells through dual biomarker recognition. The system activates cytotoxic agents only when both tumour markers are present, offering enhanced specificity over current antibody–drug conjugates while enabling deeper tissue penetration and multi-drug combinations.
-
NewsHuman antimicrobial peptide dermcidin shows antiviral activity against influenza
Researchers at Fisabio Foundation have discovered that dermcidin, an antimicrobial peptide naturally present in human sweat, exhibits antiviral activity against influenza by binding to viral haemagglutinin and preventing cell fusion, opening new possibilities for innate immunity-based therapeutics.
-
NewsMirrored molecules target disordered proteins in Alzheimer’s disease
Researchers at Kobe University have developed a novel approach to Alzheimer’s disease treatment by engineering right-handed amino acid chains that bind to amyloid-beta proteins. The method, inspired by materials science principles of chirality, demonstrated effective inhibition of toxic protein aggregation in mouse brain cell cultures, maintaining cell viability where amyloid-beta alone reduced it by 50 percent.
-
ReportCRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.
-
NewsScientists scale up neural organoid studies for drug testing
Researchers at King’s College London have developed a hybrid neural organoid approach that addresses longstanding limitations in scalability, reproducibility and longitudinal analysis. By dissociating 3D organoids and culturing pooled cells on microelectrode arrays, the team created 2D networks that retain cellular diversity whilst enabling consistent, long-term tracking of neural activity across parallel cultures.
-
NewsImplantable ‘living pharmacy’ device produces multiple drugs inside the body
Scientists have developed an implantable device that acts as a ‘living pharmacy’, using engineered cells to continuously produce multiple therapeutic biologics inside the body. The wireless system, which generates its own oxygen supply, maintained stable drug levels for 30 days in preclinical studies.
-
InterviewPhysics-based modelling offers a new way to study drug targets
Australian start-up OmnigeniQ has demonstrated what it describes as the first deterministic, physics-based computation of a human protein in its native state.